These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35122773)

  • 1. Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition.
    Maher JM; Zhang R; Palanisamy G; Perkins K; Liu L; Brassil P; McNamara A; Lo A; Hughes AD; Kanodia J; Kulyk S; Nikula KJ; Dengler HS; Scandurra A; Lua I; Harstad E
    Toxicol Appl Pharmacol; 2022 Mar; 438():115905. PubMed ID: 35122773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
    Melisi D; Oh DY; Hollebecque A; Calvo E; Varghese A; Borazanci E; Macarulla T; Merz V; Zecchetto C; Zhao Y; Gueorguieva I; Man M; Gandhi L; Estrem ST; Benhadji KA; Lanasa MC; Avsar E; Guba SC; Garcia-Carbonero R
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ALK5 inhibition in myelofibrosis.
    Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
    JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-986260, mitigates class-based cardiovascular toxicity in dogs but not rats.
    Rak GD; White MR; Augustine-Rauch K; Newsome C; Graziano MJ; Schulze GE
    J Appl Toxicol; 2020 Jul; 40(7):931-946. PubMed ID: 32061184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sympathetic transmitter norepinephrine inhibits VSMC proliferation induced by TGFβ by suppressing the expression of the TGFβ receptor ALK5 in aorta remodeling.
    Hu Z; Li B; Wang Z; Hu X; Zhang M; Chen R; Wu Q; Jia F
    Mol Med Rep; 2020 Jul; 22(1):387-397. PubMed ID: 32319652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGFβRI/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer.
    Guha M; Thibault S; Pham S; Bernales S; Pai R; Herrera FJ; Johnson TR; Vitsky A; Fernando T; Finkelstein M
    J Pharmacol Exp Ther; 2024 Oct; 391(2):335-345. PubMed ID: 39284628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration.
    Brown AP; Carlson TC; Loi CM; Graziano MJ
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):671-9. PubMed ID: 16944149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology.
    Ling LE; Lee WC
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2190-202. PubMed ID: 21619541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK5 signaling pathway mediates neurogenesis and functional recovery after cerebral ischemia/reperfusion in rats via Gadd45b.
    Zhang K; Zhang Q; Deng J; Li J; Li J; Wen L; Ma J; Li C
    Cell Death Dis; 2019 May; 10(5):360. PubMed ID: 31043581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ALK5 signaling induces physeal dysplasia in rats.
    Frazier K; Thomas R; Scicchitano M; Mirabile R; Boyce R; Zimmerman D; Grygielko E; Nold J; DeGouville AC; Huet S; Laping N; Gellibert F
    Toxicol Pathol; 2007 Feb; 35(2):284-95. PubMed ID: 17366323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-fibrotic effect of inhibition of TGFβ-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent γ-herpesvirus infection.
    Smoktunowicz N; Alexander RE; Franklin L; Williams AE; Holman B; Mercer PF; Jarai G; Scotton CJ; Chambers RC
    Dis Model Mech; 2015 Sep; 8(9):1129-39. PubMed ID: 26138704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma.
    Monsivais D; Peng J; Kang Y; Matzuk MM
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3883-3892. PubMed ID: 30655341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furin inhibition prevents hypoxic and TGFβ-mediated blood-brain barrier disruption.
    Baumann J; Huang SF; Gassmann M; Tsao CC; Ogunshola OO
    Exp Cell Res; 2019 Oct; 383(2):111503. PubMed ID: 31336100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.
    Santini V; Valcárcel D; Platzbecker U; Komrokji RS; Cleverly AL; Lahn MM; Janssen J; Zhao Y; Chiang A; Giagounidis A; Guba SC; Gueorguieva I; Girvan AC; da Silva Ferreira M; Bhagat TD; Pradhan K; Steidl U; Sridharan A; Will B; Verma A
    Clin Cancer Res; 2019 Dec; 25(23):6976-6985. PubMed ID: 31481511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of heart valve lesions by small-molecule ALK5 inhibitors.
    Anderton MJ; Mellor HR; Bell A; Sadler C; Pass M; Powell S; Steele SJ; Roberts RR; Heier A
    Toxicol Pathol; 2011 Oct; 39(6):916-24. PubMed ID: 21859884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics-based approach for efficacious human dose projection of BMS-986260, a small molecule transforming growth factor beta receptor 1 inhibitor.
    Parrish KE; Swanson J; Cheng L; Luk E; Stetsko P; Smalley J; Shu YZ; Huang J; Pabalan JG; Sun Y; Zvyaga T; Cvijic ME; Burke J; Borzilleri R; Murtaza A; Augustine K; Yang Z
    Biopharm Drug Dispos; 2021 Apr; 42(4):137-149. PubMed ID: 33354831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta1 causes pulmonary microvascular endothelial cell apoptosis via ALK5.
    Lu Q; Patel B; Harrington EO; Rounds S
    Am J Physiol Lung Cell Mol Physiol; 2009 May; 296(5):L825-38. PubMed ID: 19270180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors.
    Mansour MA; Hassan GS; Serya RAT; Jaballah MY; Abouzid KAM
    Bioorg Chem; 2024 Jun; 147():107332. PubMed ID: 38581966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signaling via Alk5 controls the ontogeny of lung Clara cells.
    Xing Y; Li C; Li A; Sridurongrit S; Tiozzo C; Bellusci S; Borok Z; Kaartinen V; Minoo P
    Development; 2010 Mar; 137(5):825-33. PubMed ID: 20147383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.